Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

Vaccine

Volumn 28, Issue 47, 2010, Pages 7476-7482

  Gates, Jeremy D ^a   Clifton, Guy T ^a   Benavides, Linda C ^a   Sears, Alan K ^b   Carmichael, Mark G ^c   Hueman, Matthew T ^d   Holmes, Jarrod P ^c   Jama, Yusuf H ^c   Mursal, Mohamed ^c   Zacharia, Athina ^c   Ciano, Kathy ^c   Khoo, Steven ^c   Stojadinovic, Alexander ^e   Ponniah, Sathibalan ^c   Peoples, George E ^a,c  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b LANDSTUHL REGIONAL MEDICAL CENTER   (Germany)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

HER2 neu; Regulatory T cell; Vaccine

Indexed keywords

ACETYLLEUCYLARGINYLMETHIONYLLYSYLGLYCYLVALYLGLYCYLSERYLPROLYLTYROSYLVALYLSERYLARGINYLLEUCYLLEUCYLGLYCYLISOLEUCYLCYSTEINYLLEUCINAMIDE; AE 37; CANCER VACCINE; CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER PATIENT; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE;

BREAST NEOPLASMS; CANCER VACCINES; FEMALE; GENES, MHC CLASS II; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; RECEPTOR, ERBB-2; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 77958196145     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.029     Document Type: Article

References (59)

1. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004, 22(6):1136-1151.
2. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21(2):137-148.
3. Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970, 18(5):723-737.
4. Bachetta R., Gambineri E., Roncarolo M. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007, 120(2):227-235.
5. Meric F., Hung M.C., Hortobagyi G.N., Hunt K.K. HER2/neu in the management of invasive breast cancer. J Am Coll Surg 2002, 194(4):488-501.
6. SEER cancer statistics review, 1975-2003 2006, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site. L.A.G. Ries, D. Harkins, M. Krapcho, A. Mariotto, B.A. Miller, E.J. Feuer (Eds.).
7. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxol or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354(8):809-820.
8. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
9. Pritchard K.I., Shepherd L.E., O'Malley F.P., Andrulis I.L., Tu D., Bramwell V.H., et al. National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006, 354(20):2103-2111.
10. Ioannides C.G., Fisk B., Fan D., Biddison W.E., Wharton J.T., O'Brian C.A. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993, 151(1):225-234.
11. Yoshino I., Goedegebuure P.S., Peoples G.E., Parikh A.S., DiMaio J.M., Lyerly H.K., et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994, 54(13):3387-3390.
12. Disis M.L., Smith J.W., Murphy A.E., Chen W., Cheever M.A. In vitro generation of human cytolic T-cells specific for peptide derived from the HER-2/neu protooncogene protein. Cancer Res 1994, 54(4):1071-1076.
13. Peoples G.E., Goedegebuure P.S., Smith R., Linehan D.C., Yoshino I., Eberlein T.J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995, 92(2):432-436.
14. Fisk B., Blevins T.L., Wharton J.T., Ioannides C.G. Identification of an immunodominant peptide of the HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995, 181(6):2109-2117.
15. Mittendorf E.A., Holmes J.P., Ponniah S., Peoples G.E. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008, 57(10):1511-1521.
16. Mittendorf E.A., Storrer C.E., Foley R.J., Harris K., Jama Y., Shriver C.D., et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006, 106(11):2309-2317.
17. Bourgeois C., Rocha B., Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002, 297(5589):2060-2063.
18. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393(6684):474-478. [see comments].
19. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393(6684):480-483.
20. Kallinteris N.L., Powell D., Blackwell C.E., Kim M., Lu X., Wu S., et al. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front Biosci 2006, 11(1):46-58.
21. Xu M., Li J., Gulfo J.V., von Hofe E., Humphreys RE MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001, 54(1-2):39-44.
22. Kallinteris N.L., Wu S., Lu X., Humphreys R.E., von Hofe E., Xu M. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope. J Immunother 2005, 28(4):352-358.
23. Sotiriadou N.N., Kallinteris N.L., Gritzapis A.D., Voutsas I.F., Papamichail M., von Hofe E., et al. Ii-Key/HER-2/neu (776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 2007, 56(5):601-613.
24. Holmes J.P., Benavides L.C., Gates J.D., Carmichael M.G., Hueman M.T., Mittendorf E.A., et al. Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008, 26(20):3426-3433.
25. Peoples G.E., Gurney J.M., Hueman M.T., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high risk breast cancer patients. J Clin Oncol 2005, 23:7536-7545.
26. Hueman M.T., Dehqanzada Z.A., Novak T.E., Gurney J.M., Woll M.M., Ryan G.B., et al. Phase I of a HER-2/neu peptide (E75) for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 2005, 11(20):7470-7479.
27. Woll M.M., Fisher C.M., Ryan G.B., Gurney J.M., Storrer C.E., Ioannides C.G., et al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol 2004, 24(4):449-461.
28. Sokal J.E. Editorial: measurement of delayed skin-test responses. N Engl J Med 1975, 293(10):501-502.
29. Humphreys R.E., Adams S., Koldzic G., Nedelescu B., von Hofe E., Xu M. Increasing the potency of MHC class II-presented epitopes by linking to Ii-Key peptide. Vaccine 2000, 18(24):2693-2697.
30. Gillogly M.E., Kallinteris N.L., Xu M., Gulfo J.V., Humphreys R.E., Murray J.L. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004, 53(6):490-496.
31. Sotiriadou R., Perez S.A., Gritzapis A.D., Sotiropoulou P.A., Echner H., Heinzel S., et al. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 2001, 85(10):1527-1534.
32. Voutsas I.F., Gritzapis A.D., Mahaira L.G., Salagianni M., von Hofe E., Kallinteris N.L., et al. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 2007, 121(9):2031-2041.
33. Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of Immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999, 5(6):1289-1297.
34. Liyanage U.K., Moore T.T., Joo H., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169(5):2756-2761.
35. Hueman M.T., Stojadinovic A., Storrer C.E., Foley R.J., Gurney J.M., Shriver C.D., et al. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Br Cancer Res Treat 2006, 98(1):17-29.
36. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24(34):5373-5380.
37. Merlo A., Casalini P., Carcangiu M.L., Malventano C., Triulzi T., Mènard S., et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009, 27(11):1746-1752.
38. Fujimoto S., Greene M., Sehon A.H. Immunosuppressor T cells in tumor bearing host. Immunol Commun 1975, 4(3):201-217.
39. Berendt M.J., North R.J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980, 151(1):69-80.
40. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155(3):1151-1164.
41. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4(4):330-336.
42. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299(5609):1057-1061.
43. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001, 194(5):629-644.
44. Yamagiwa S., Gray J.D., Hashimoto S., Horwitz D.A. Role for TGF-β in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001, 166(12):7282-7289.
45. Peng Y., Laouar Y., Li M.O., Green E.A., Flavell R.A. TGF-β regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004, 101(13):4572-4577.
46. Zhou G., Drake C.G., Levitsky H.I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006, 107(2):628-636.
47. Chakraborty N.G., Chattopadhyay S., Mehrotra S., Chhabra A., Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphoctyes in human melanoma. Hum Immunol 2004, 65(8):794-802.
48. Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Löwik M.J., Berends-van der Meer D.M., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008, 14(1):178-187.
49. Svane I., Pedersen A., Nikolajsen K., Zocca M. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine 2008, 26(36):4716-4724.
50. Cipriani B., Fridman A., Bendtsen C., Dharmapuri S., Mennuni C., Pak I., et al. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 2008, 19(7):670-680.
51. Papewalis C., Wuttke M., Jacobs B., Domberg J., Willenberg H., Baehring T., et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008, 40(2):108-116.
52. Hus I., Schmitt M., Tabarkiewicz J., Radej S., Wojas K., Bojarska-Junak A., et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008, 22(5):1007-1017.
53. Hao S., Liu Y., Yuan J., Zhang X., He T., Wu X., et al. Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+CD25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses. J Immunol 2007, 179(5):2731-2740.
54. Comes A., Rosso O., Orengo A.M., Di Carlo E., Sorrentino C., Meazza R., et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometasteses by the IL-21-secreting cellular vaccine. J Immunol 2006, 176(3):1750-1758.
55. Johnson B.D., Jing W., Orentas R.J. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007, 30(2):203-214.
56. Nair S., Boczkowski D., Fassnacht M., Pisetsky D., Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enchances tumor immunity. Cancer Res 2007, 67(1):371-380.
57. Morse M.A., Hobeika A.C., Osada T., Serra D., Niedzwiecki D., Lyerly H.K., et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112(3):610-618.
58. Litzinger M.T., Fernando R., Curiel T.J., Grosenbach D.W., Schlom J., Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110(9):3192-3201.
59. Mukherjee P., Basu G.D., Tinder T.L., Subramani D.B., Bradley J.M., Arefayene M., et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. Immunology 2009, 182(1):216-224.